On October 13, 2020 Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics, with a focus on oncology and infectious diseases, including COVID-19, reported the full exercise of the underwriters’ option to purchase an additional 487,500 shares of common stock at the public offering price of $12.00 per share, resulting in additional gross proceeds of approximately $5.9 million, in connection with the Company’s previously announced initial public offering of common stock (Press release, Immunome, OCT 13, 2020, View Source [SID1234568424]). After giving effect to the full exercise of the over-allotment option, the total number of shares sold by Immunome in the initial public offering was 3,737,500 shares and the gross proceeds were approximately $44.9 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by the Company. All of the shares were sold by Immunome. Immunome’s common stock began trading on the Nasdaq Capital Market on October 2, 2020, under the ticker symbol "IMNM".
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Ladenburg Thalmann & Co. Inc. and Chardan acted as book-running managers for the offering.
A registration statement relating to the offering of these securities has been declared effective by the Securities and Exchange Commission on October 1, 2020. The offering was made only by means of a prospectus. Copies of the final prospectus relating to the offering may be obtained by vising www.sec.gov or from Ladenburg Thalmann & Co. Inc., 277 Park Avenue, 26th Floor, New York, NY 10172, or by calling (212) 409-2000, or by emailing [email protected] or Chardan Capital Markets, LLC, 17 State Street, 21st floor, New York, New York 10004, or by calling (646) 465-9001.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.